Concluding remarks

Dermatology

Volumn 194, Issue 1, 1997, Pages 48-49

  Birnbaum, J E ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

DERMATOPHYTE; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TISSUE LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; MYCOSIS; PRIORITY JOURNAL; SHORT SURVEY; SKIN TOXICITY; SYMPOSIUM; TASTE DISORDER;

EID: 0030985720     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000246187     Document Type: Article

References (1)

1. De Keyser P. De Backer M, Massert DL. Westelinck KJ: Two week treatment of tinea pedis, comparing terbinafinc (250 mg daily) with itraconazole (100 mg daily): A double-blind, multicentrc study. Br J Dermatol 1994:130 (suppl 43):22-25.